Navigation Links
Promotion of Pneumococcal Vaccine Slow in Europe

A study published in the April issue of IJCP, the International Journal of Clinical Practice reveals that although 90 per cent of cases of invasive// pneumococcal diseases (IPD) like meningitis - occur in healthy young children many European countries still only vaccinate selected at-risk groups against IPD.

This is despite growing evidence that universal vaccination of infants and young children reduces their risk and also provides added indirect "herd" protection for other unvaccinated members of the community. .

Children in high risk groups include those with underlying medical conditions, such as sickle cell disease, HIV or diabetes. .

The general European situation contrasts with the United States, which adopted universal vaccination with the 7-valent pneumococcal conjugate vaccine in August 2000, following the advice of the US Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics. .

The CDC recommended vaccinations for infants and children under two years-old, with catch-up vaccinations targeted at children aged two to five years with particular health problems. US authorities also highlighted the need for certain minority and ethnic groups to be added to the list, together with children attending day care. .

A European assessment carried out by the authors in August 2005 showed that most countries - Belgium, Germany, Denmark, Finland, the UK, Ireland, Iceland, Norway, Portugal and Sweden - did not offer universal national or regional IPD immunisations, while Austria and France provided the most comprehensive guidelines for vaccinating at-risk groups. .

Since then the UK Government has announced that the 7-valent pneumococcal conjugate vaccine will be added to childhood immunisation programmes from this year, pointing out the "immense impact" it has had in the US. .

The Netherlands has also announced that the vaccine will be include in the n ational childhood immunisation programme from April 2006. .

"Restricting pneumococcal immunisation to children who have a serious health problem that could make them more susceptible means that only a small percentage of the overall cases of childhood IPD may be prevented. Herd protection cannot be achieved without broad vaccine coverage" says lead author Dr Mark Fletcher, Director of International Scientific and Clinical Affairs at Wyeth Vaccine Research, Paris. Most children hospitalised for IPD do not belong to a recognised at-risk group, he adds. Surveys in the US and Europe have shown that only ten to 27 per cent of children developing IPD have an underlying health problem. .

Certain factors increase the risk for IPD. For example: Children who attend group day care face a two to three times greater risk than children who stay at home. .

Low birth-weight babies face a 2.6 greater risk than normal birth-weight babies and premature babies face a 1.6 greater risk than full-term babies. .

Rates increase dramatically if children have conditions such as HIV and AIDS (11,300 cases a year per 100,000 children under three) or sickle cell disease (5,500 to 6,500 cases a year per 100,000 children under five). .

Surveys carried out in the US before the 7-valent pneumococcal conjugate vaccine was universally introduced there showed that African American children under the age of two had a 1.6 greater risk than white children of the same age. .

The IJCP paper also carries a detailed analysis of vaccine prescriptions in the UK, which shows that at least 4,080 children received the pneumococcal vaccine between January 2002 and August 2004. .

Research carried out with child experts in various medical specialties identified that UK children with nine key illnesses received the vaccine. Children suffering from coeliac disease were the largest group (34 per cent), followed by sickle cell disease (15 p er cent) and chronic cardiac disease (12 per cent). .

Other illnesses included cystic fibrosis, chronic liver disease, renal failure, chronic lung disease and HIV. .

"But identifying high-risk individuals is often difficult and pneumococcal vaccination programmes that target only certain subpopulations will still miss people who could develop pneumococcal disease" concludes Dr Fletcher. .

"US studies carried out since the introduction of universal vaccination show that IPD has fallen among vaccinated groups and has also led to a decrease in non-vaccinated groups. .

"For example, studies published in 2005 show that three years after routine vaccination was introduced in the US, the CDC noted a 94 per cent reduction in IPD caused by strains covered in the vaccine in children under five years old. .

"In addition, the incidence of disease caused by these strains fell by 55 per cent among adults aged 50 years or older, who tend to be more susceptible to IPD than younger adults. This clearly demonstrates that universally vaccinating children provides herd protection for other unvaccinated groups. .

"Based on the success of the US experience, universal vaccination appears to be the most effective option for protecting all children, including those who are at risk simply because of their young age. .

"An added bonus is that it also appears to protect other unvaccinated members of the community. .


'"/>




Related medicine news :

1. Promotion Of Medical Research In India Is The Need Of The Hour: ICMR
2. Health Promotion Drives Waste Money, Claim Nurses
3. Indian Health Ministry Bags US Award for Health Promotion and Tobacco Control
4. Junk Food Promotional Ads To Be Restricted: Blair
5. Condom Promotion-Crucial To HIV/AIDS Prevention
6. Pneumococcal Vaccine: Childhood Immunization Programme has a new recruit
7. Intro of Pneumococcal Vaccines: Experts Urge Commitment From Industry
8. Wyeth Launches Vaccine for Pneumococcal Disease in India
9. March towards Free Pneumococcal Vaccine
10. Immunisation programme to include vaccine against Pneumococcal disease
11. New Vaccine to Combat Pneumococcal Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: